Developing a drug for late-stage brain cancer. Brain tumor clinical trial underway for AA3 or Grade 3 glioma.
Location: Canada
Total raised: $103.5M
Investors 7
Funding Rounds 2
| Date | Series | Amount | Investors |
| 23.10.2020 | Series A | $71M | H.I.G. Bio... |
| 20.08.2015 | Series A | $32.5M | - |
Mentions in press and media 6
| Date | Title | Description |
| 19.01.2022 | Orbus Therapeutics’ Phase 3 Eflornithine STELLAR Study Reaches Full Patient Enrollment | - Phase 3 STELLAR trial evaluating eflornithine in patients with recurrent anaplastic astrocytoma - - Pre-specified interim analysis to test for superiority expected to occur in 2022 - PALO ALTO, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Or... |
| 22.10.2020 | Orbus Therapeutics Expands Series A Financing to $71 Million to Support Ongoing STELLAR Phase 3 Study in Rare Brain Cancer | - |
| 21.08.2015 | Orbus gets $32.5M to repurpose hirsutism drug for brain cancer | Orbus has found that eflornithine can improve survival rates among patients with newly diagnosed or recurrent anaplastic astrocytoma – a rare and malignant form of brain cancer. It works, ostensibly, by slowing down the rapid division of ca... |
| 20.08.2015 | Orbus Therapeutics Completes $32.5M Series A Financing | Orbus Therapeutics Inc., a Palo Alto, CA-based clinical-stage biopharmaceutical company, completed a $32.5m Series A financing. The round was led by Longitude Capital, H.I.G. BioVentures and Adams Street Partners. Dr. Ernest Mario also part... |
| 20.08.2015 | Orbus Therapeutics Secures $32.5M | PALO ALTO, CA, Orbus Therapeutics today announced the completion of a $32.5 million Series A financing. >> Click here for more funding data on Orbus Therapeutics >> To export Orbus Therapeutics funding data to PDF and Excel,... |
| - | Orbus gets $32.5M to repurpose hirsutism drug for brain cancer | An already-approved drug used to treat excess facial hair and sleeping sickness may have an important new purpose: Treating brain cancer. Palo Alto-based Orbus Therapeutics will be kicking off Phase 3 trials to study the effect of FDA-appro... |